Two recent papers demonstrate that the 'tubulin code' -the pattern of chemical modifications of tubulin along a microtubule -is disrupted upon deletion or mutation of an enzyme, called CCP1, that removes one of these modifications. Ablation of CCP1 interferes with mitochondrial transport and causes human neurodegenerative disease, which may be amenable to pharmacological therapies.
Histone modifications alter the conformation of folded chromatin and, in turn, change the propensity for genes to be transcribed or silenced. This is referred to as the 'histone code' [1] , as the distribution of histone modifications dictates the 'rules' for how RNA polymerases travel along the chromatin 'road', just as a car proceeding down the street is governed by what the French call the 'Code de la Route'. Genetic mutations of enzymes that add or remove these modifications alter the histone code and this effects gene expression changes that alter the cellular phenotype. In some cases, alterations in the histone code prevent RNA polymerases from traveling down the correct route, leading to developmental abnormalities, improper growth regulation, or cancer. Pharmacological interventions, most notably with inhibitors of histone deacetylases, have been used therapeutically to attempt to restore growth control or to ameliorate a disease state.
A decade and a half after Strahl and Allis proposed the histone code [1] , Janke proposed an analogous 'tubulin code' [2] . A plethora of reversible post-translational modifications of tubulin subunits had been characterized and nearly all of them had been shown to change the structure of the microtubule surface and thus its capacity to interact with microtubuleassociated proteins and to serve as a track for molecular motors [3] . The tubulin code hypothesis proposed that genetic alterations in any of the enzymes that add or remove these tubulin modifications would alter the rules of the microtubule road. Like the histone code, altering the tubulin code might be expected to result in concomitant pathologies in cells or organisms, possibly even causing developmental problems or diseases in humans.
In a recent issue of EMBO Journal, two papers [4, 5] demonstrate that the sequelae of ablating an enzyme that removes one of these tubulin modifications provides proof-of-principle for the tubulin code: mutating or deleting cytosolic carboxypeptidase 1 (CCP1), a tubulin deglutamylase, is sufficient to decrease mitochondrial transport on microtubule tracks, kill neurons, and cause a human neurodegenerative disease. These are landmark studies because they identify a gene defect that causes a human disease and they provide mechanistic information from mouse models and studies of cultured neurons. Furthermore, these two papers support current theories of neuropathology; for example, that axonal transport deficits are a unifying feature of neurodegenerative disorders [6] , and that cytoskeleton and transport defects may be those most amenable to therapeutic intervention [7] . Finally, the goal of identifying genes that cause neurodegeneration has been a kind of Holy Grail. These papers are notable because they demonstrate that a single gene defect is sufficient to cause a distinct neurodegenerative disorder in mice and in humans, which seems to be an advance compared with most other studies that have elucidated gene mutations that put individuals at risk for neurodegeneration but may not actually be causal [8] .
After the complex set of enzymes that add [9,10] and remove [11, 12] glutamates from tubulin had been identified and cloned, Janke's laboratory began to test the tubulin code hypothesis by a systematic determination of the phenotypes resulting from the deletion or overexpression of the genes encoding each enzyme. CCP1 might appear to be the natural starting point for these studies; however, the real reason for the initial focus on CCP1 was that the discoverers of the CCP (also known as Nna) gene family had shown that mice with the neurodegenerative disease Purkinje cell degeneration (pcd mice [13] ) had mutations in the CCP1/Nna1 gene [14] .
Accordingly, Magiera et al. [4] generated mice that were null for CCP1 and determined that they indeed show Purkinje cell degeneration with juvenile onset. They also showed hyperglutamylation of microtubules within the neurons in these mice. Most importantly, they demonstrated that glutamylation level, rather than the increased microtubule severing that would be expected to result from hyperglutamylation of microtubules [15] , was the cause of the neurodegeneration, since neuronal death was averted when the researchers also made targeted deletions in Purkinje cells of the gene encoding the predominant glutamylation enzyme, TTLL1, but not the gene encoding the spastin severing enzyme that is induced by increased glutamylation. This result is especially promising as it suggests that pharmacological inhibition of TTLL1 could provide a therapeutic avenue.
Next, Magiera et al. [4] examined whether transport defects could be the mechanism for neuronal degeneration. Assaying mitochondrial transport on microtubules, the group found no change in speed or run-time of bidirectional mitochondrial movement, but overall mitochondrial motility was reduced by about one-half ( Figure 1 ). Although it is not yet known whether microtubule motors that transport other cargoes in the axon are similarly affected, this finding is consistent with a recent report from Gilmore-Hall et al. [16] . It should be noted that the latter investigators found retrograde transport to be more affected than anterograde and they also noted alterations in mitochondrial fission that may contribute to the neurodegeneration phenotype.
The second, related paper, from a large consortium headed by Shashi, Magiera, et al. [5] , is striking as it adds a human, translational dimension to the studies on CCP1 and on mouse genetics, and provides proof that the tubulin code is no fanciful imitation of the histone code. This paper describes human infantile-onset neurodegeneration patients whose genetic mutations result in non-functional CCP1 and thus have hyperglutamylated tubulin. This human neurodegenerative disease affects cerebellar neurons, closely mirroring the pcd mouse, but it also shows degeneration of spinal motor neurons and peripheral nerves. Shashi, Magiera, et al. [5] revisited the pcd mouse and found that, in more than 40 years of study, researchers had missed the fact that pcd mice also show peripheral nerve and spinal motor neuron degeneration. Thus, the pcd mouse and the human disease both identify a single gene that is sufficient to cause a specific neurodegenerative disease. Further, the rescue of the neurodegenerative phenotype of the pcd mice by ablating the gene for the glutamylation enzyme, TTLL1, suggests a pharmacological strategy that could work in humans: pharmacological inhibition of the TTLL1 enzyme in humans offers a real possibility of therapeutic treatments for humans with infantile-onset neurodegeneration caused by CCP1 mutations. This work also suggests that, given the long lifespan of humans, a more subtle increase in glutamylation might cause neurodegeneration later in life, given that marked increases in glutamylation cause them to manifest neurodegeneration as infants.
In summary, the two papers highlighted here [4, 5] significantly advance evidence of the tubulin code. In fact, this work may even bring validation of the tubulin code ahead of or at least on par with substantiation of the histone code because, for the latter, the loss of genes encoding the modifying enzymes has only been shown to directly cause human disease in a few instances, with most examples pointing instead to gene linkage or simply to a correlation with disease. It is now clear that both histone and tubulin modifications specify a 'Code de la Route' that ultimately dictates the phenotype and pathology of cells and organisms. This cartoon of a neuronal cell shows a microtubule that is heavily glutamylated (shown with orange and red glutamic acid (E) residues appended), and another microtubule that is devoid of glutamylation. Mitochondria are shown as either moving bidirectionally, that is, attached to little wheels connoting the kinesin (anterograde) and dynein (retrograde) motors allowing them to move on microtubules, or stationary, without motor or microtubule attachment. The road signs illustrate how the tubulin code serves to regulate transport on the microtubule tracks: a 'Do Not Enter' sign at each end of the glutamylated microtubule prevents mitochondria from being transported on the glutamylated roadway, while the 'Priority Roadway' sign on each end of the non-glutamylated microtubule indicates mitochondria are able to travel freely along the non-glutamylated track. The figure has been simplified to show only two microtubules in the neuron, to indicate only abundant glutamylation vs. no glutamylation, and to show a complete blockage of mitochondrial transport on the glutamylated microtubule (although data in the Magiera et al. [4] paper show a 50% reduction rather than a complete blockage). Current Biology 29, R16-R37, January 7, 2019 R29
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Dispatches
Using genome editing and advanced light microscopy, a recent study has offered new insights into the dynamic assembly and disassembly of the exocyst complex during vesicle tethering and membrane fusion.
Exocytosis -the transport of secretory vesicles to the plasma membrane for fusion -plays important roles in cell morphogenesis, growth, division, migration and signaling. The exocyst is an evolutionarily conserved heterooctameric complex consisting of Sec3, Sec5, Sec6, Sec8, Sec10, Sec15, Exo70 and Exo84 subunits [1] [2] [3] . The primary function of the exocyst is to mediate the tethering of secretory vesicles to the plasma membrane before SNAREmediated fusion [4] . Using CRISPR-Cas9-mediated gene editing, light microscopic imaging and correlation spectroscopy, Ahmed and colleagues [5] have now provided us with new insight into the dynamics of the exocyst complex during exocytosis.
Since the early purifications from yeast in 1995 [1, 2] , intensive effort has been made to understand the architecture and assembly of the exocyst complex [6] . Two interaction studies in yeast and mammalian cells have suggested the existence of two subcomplexes consisting of Sec3-Sec5-Sec6-Sec8 ('subcomplex I'), and Sec10-Sec15-Exo70-Exo84 ('subcomplex II'), respectively [7, 8] . Most recently, cryo-electron microscopy studies revealed that the formation of the two subcomplexes is mediated by fourhelix bundles consisting of the conserved CorEx ('core of exocyst') motif from each of the subunits [9] . The two subcomplexes then, like two hands, clasp each other to form the octameric holo-complex [9] .
While the structural studies have advanced our understanding of the fully assembled exocyst complex, it is also important to elucidate how the exocyst assembles during vesicle transport, tethering and fusion. To understand the dynamics of exocyst assembly in exocytosis, earlier work by Boyd and colleagues [10] elegantly combined fluorescence recovery after photobleaching (FRAP) and immunogold electron microscopy to monitor each of the eight subunits of the complex in yeast cells. They demonstrated that a subset of exocyst subunits (Sec5, Sec6, Sec8, Sec10, Sec15, Exo84 and some of Exo70) ride the vesicles along the actin cables to the daughter cell ('bud'), where they assemble with Sec3 at the plasma membrane. Also using yeast, Donovan and Bretscher [11] reported that the secretory vesicles are tethered to the plasma membrane for around 18 seconds until membrane fusion, and that Sec3, Sec5 and Sec15 leave the vesicles coincident with fusion. These studies have provided important information on the dynamics of exocyst action during exocytosis in yeast. However, some questions remained open: how are the exocyst subunits organized on the vesicles? Is there pre-assembly of the subunits before recruitment onto the vesicle? Moreover, how is the exocyst assembled during exocytosis in mammalian cells? A major challenge to the tracking of the exocyst in mammalian cells is that overexpression of individual exocyst subunits may cause their mislocalization, aggregation and degradation [12] . By silencing endogenous Sec8 and replacing it with Sec8-RFP at a low expression level, Rivera-Molina and Toomre [12] showed that, in HeLa cells, Sec8 arrives at the plasma membrane on vesicles around 7.5 seconds prior to vesicle fusion and leaves 2 seconds after fusion.
In the new study, Ahmed et al. [5] used CRISPR-Cas9-mediated gene editing to generate an array of cell lines expressing exocyst subunits tagged with fluorescent proteins. Immunoprecipitation experiments revealed the interactions of all the exocyst subunits and their known binding partners such as small GTPases in these cells, confirming the functionality of the tagged exocyst subunits. When Sec8,
